Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: Summary of primary findings and conclusions

Archives of Internal Medicine

Volumn 172, Issue 13, 2012, Pages 1014-1015

  O'Malley, Patrick G ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB;

CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; DIABETIC MACULAR EDEMA; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; LASER COAGULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; COMPARATIVE EFFECTIVENESS RESEARCH; DIABETIC RETINOPATHY; DRUG COSTS; EVIDENCE-BASED MEDICINE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; OFF-LABEL USE; RECOMBINANT FUSION PROTEINS; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863707144     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.2335     Document Type: Short Survey

References (7)

1. Anti-vascular endothelial growth factor treatment for diabetic macular edema. US Department of Health and Human Services Web site. https://www.cms.gov/ medicare-coverage-database/details/technology-assessments-details.aspx?&bc= BAAAAAAAAAAA&MEDCACId=60&TAId=85&#ResultsSection. Accessed April 30, 2012.
2. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128(10):1273-1279.
3. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
4. Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond). 2010;24(11):1708-1715.
5. Bethke W. For DME, one size does not fit all. Review of Ophthalmology Web site. http://www.revophth.com/content/i/1599/c/29625/. Accessed April 30, 2012.
6. Boscia F. Current approaches to the management of diabetic retinopathy and diabetic macular oedema. Drugs. 2010;70(16):2171-2200.
7. Steinbrook R. The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355(14):1409-1412. (Pubitemid 44511554)